GeneDx Holdings Corp. (WGS) announced preliminary results on Monday, indicating a year-over-year increase of 59% for the fourth quarter and 54% for the full year of 2024. The company's quarterly revenue is projected to be at least $92 million, with the full-year revenue estimated to be at least $299 million.
Analysts, on average, have forecasted fourth-quarter revenue at $80.22 million and full-year revenue at $288.2 million.
At present, GeneDx's stock is experiencing a decrease of 4.13%, trading at $85.69 on the Nasdaq.
